Endocannabinoids control spasticity in a multiple sclerosis model.

Endocannabinoids control spasticity in a multiple sclerosis model.

Spasticity is a complicating sign in multiple sclerosis that also develops in a model of chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice. In areas associated with nerve damage, increased levels of the endocannabinoids, anandamide (arachidonoylethanolamide, AEA) and 2-arac...

Full description

Bibliographic Details
Main Authors:	Baker, D, Pryce, G, Croxford, J, Brown, P, Pertwee, R, Makriyannis, A, Khanolkar, A, Layward, L, Fezza, F, Bisogno, T, Di Marzo, V
Format:	Journal article
Language:	English
Published:	2001

Similar Items

Cannabinoids control spasticity and tremor in a multiple sclerosis model.
by: Baker, D, et al.
Published: (2000)

Endocannabinoid signalling in the blood of patients with schizophrenia
by: Orlando Pierangelo, et al.
Published: (2003-08-01)

Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis
by: Ana Cabranes, et al.
Published: (2005-11-01)

Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors.
by: Brooks, J, et al.
Published: (2002)

Endocannabinoid Signaling Regulates Sleep Stability.
by: Matthew J Pava, et al.
Published: (2016-01-01)

An expert opinion: Optimisation of pharmacological management of multiple sclerosis related spasticity
by: Rachel Farrell, et al.
Published: (2019-10-01)

Spasticity, spastic dystonia, and static stretch reflex in hypertonic muscles of patients with multiple sclerosis
by: Luca Puce, et al.
Published: (2021-01-01)

Endocannabinoids, Related Compounds and Their Metabolic Routes
by: Filomena Fezza, et al.
Published: (2014-10-01)

Endocannabinoids generated by Ca2+ or by metabotropic glutamate receptors appear to arise from different pools of diacylglycerol lipase.
by: Longhua Zhang, et al.
Published: (2011-01-01)

Treatments for spasticity and pain in multiple sclerosis: a systematic review
by: S Beard, et al.
Published: (2003-12-01)

Clinical insights on the spasticity-plus syndrome in multiple sclerosis
by: Kanza Alami Marrouni, et al.
Published: (2022-08-01)

Biomechanical analysis of spasticity treatment in patients with multiple sclerosis
by: Michael Wininger, et al.
Published: (2015-09-01)

Endocannabinoid System and the Role of Medical Cannabis in Treating Spasticity: A Narrative Review
by: Navarro, Cristian Eduardo
Published: (2024-01-01)

A evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols
by: Clara Grazia Chisari, et al.
Published: (2023-09-01)

New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids
by: Paul F Smith
Published: (2010-02-01)

Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis.
by: Bass, B, et al.
Published: (1988)

Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis
by: Federica Novarella, et al.
Published: (2022-11-01)

The coexistence of multiple sclerosis and hereditary spastic paraparesis in a patient
by: Işıl Yazıcı, et al.
Published: (2013-06-01)

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity
by: Verena Isabell Leussink, et al.
Published: (2012-09-01)

Protective activation of the endocannabinoid system during ischemia in dopamine neurons
by: Miriam Melis, et al.
Published: (2006-10-01)

Alterations of the endocannabinoid system and circulating and peripheral tissue levels of endocannabinoids in sarcopenic rats
by: Olivier Le Bacquer, et al.
Published: (2022-02-01)

Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria
by: Michael Guger, et al.
Published: (2023-04-01)

The Endocannabinoid System: A Bridge between Alzheimer’s Disease and Gut Microbiota
by: Tiziana Bisogno, et al.
Published: (2021-09-01)

Evaluation of the Multiple Sclerosis Spasticity Scale 88: A Short Report
by: Jenny Freeman, et al.
Published: (2019-01-01)

BIONOTE as an Innovative Biosensor for Measuring Endocannabinoid Levels
by: Simone Grasso, et al.
Published: (2021-01-01)

Endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarate
by: Alicia Sánchez-Sanz, et al.
Published: (2022-11-01)

Spasticity-Plus syndrome in multiple sclerosis patients in a tertiary hospital in Spain
by: Haydee Goicochea Briceño, et al.
Published: (2024-02-01)

Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity
by: Alberto Gajofatto, et al.
Published: (2023-03-01)

The protective effects of lavender herbal tea on spasticity and ataxia in patients with multiple sclerosis
by: Nahid Jivad, et al.
Published: (2023-06-01)

Validation of the Serbian Version of Multiple Sclerosis Spasticity Scale 88 (MSSS-88).
by: Sindi Z Rodic, et al.
Published: (2016-01-01)

Avascular Necrosis of Femoral Head Which Maybe Confused with Multiple Sclerosis Spasticity in a Multiple Sclerosis Patient: Case Report
by: Fatih Baygutalp, et al.
Published: (2015-12-01)

Limited Access to a High Fat Diet Alters Endocannabinoid Tone in Female Rats
by: Valentina Satta, et al.
Published: (2018-02-01)

Goal-Setting in Multiple Sclerosis-Related Spasticity Treated with Botulinum Toxin: The GASEPTOX Study
by: Ines Baccouche, et al.
Published: (2022-08-01)

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review
by: Rowland Marie, et al.
Published: (2009-12-01)

Effect of dynamic neuromuscular stabilization on fatigue and spasticity in people with multiple sclerosis: a randomized controlled trial (ORP-37)
by: Laleh Abadi Marand
Published: (2023-01-01)

A Study on the Effects of Dry Needling in Multiple Sclerosis Patients with Spasticity: Protocol of a Randomized Waitlist-Controlled Trial
by: Omid Motamedzadeh, et al.
Published: (2021-04-01)

TIZANIDINE VERSUS BACLOFEN IN THE TREATMENT OF SPASTICITY IN PATIENTS WITH MULTIPLE-SCLEROSIS - A DOUBLE-BLIND-STUDY
by: Bass, B, et al.
Published: (1987)

Transcutaneous Spinal Cord Stimulation Enhances Walking Performance and Reduces Spasticity in Individuals with Multiple Sclerosis
by: Ursula S. Hofstoetter, et al.
Published: (2021-04-01)

Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
by: Marie D’hooghe, et al.
Published: (2021-06-01)

Subscales correlations between MSSS-88 and PRISM scales in evaluation of spasticity for patients with multiple sclerosis
by: Knežević Tatjana, et al.
Published: (2017-01-01)